Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Corporation

In a report released on April 2, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Boston Scientific, with a price target of $115.00....

Boston Scientific (BSX) Receives a Buy from RBC Capital

In a report released yesterday, Hans Engel from Erste Group assigned a Hold rating to Boston Scientific. The company’s shares closed today at $62.0...

Boston Scientific (BSX) Gets a Hold from Erste Group

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Boston Scientific (BSX) and Alto Neuroscience, Inc. ...

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Alto Neuroscience, Inc. (ANRO)

Boston Scientific (BSX) projected strong growth. They said their heart-device technology was gaining share in the market. Investors were told the m...

Boston Scientific Investors File Lawsuit Over Alleged Misleading Statements About Electrophysiology Business Growth 

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Boston Scientific (BSX) and Abbott Laboratories (ABT...

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Abbott Laboratories (ABT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tonix Pharma (TNXP), Alumis Inc. (ALMS) and Boston S...

Analysts Offer Insights on Healthcare Companies: Tonix Pharma (TNXP), Alumis Inc. (ALMS) and Boston Scientific (BSX)

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Boston Scientific today and set a price target of $115.00. Singh Chadha covers t...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Boston Scientific (BSX) and Monopar Therapeutics Inc...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Barclays analyst Matt Miksic reiterated a Buy rating on Boston Scientific today and set a price target of $124.00. Miksic covers the Healthcare sec...

Barclays Sticks to Its Buy Rating for Boston Scientific (BSX)

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Boston Scientific on March 25 and set a price target of $115.00. The company’s s...

Boston Scientific (BSX) Gets a Buy from RBC Capital

Jefferies analyst Matthew Taylor maintained a Buy rating on Boston Scientific today and set a price target of $120.00. Taylor covers the Healthcare...

Jefferies Remains a Buy on Boston Scientific (BSX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on enGene Holdings (ENGN) and Boston Scientific (BSX). enGene Holdin...

Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Boston Scientific (BSX)

IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Diversification and Growth to Investors

Boston Scientific ($BSX) told investors its heart rhythm business was growing fast. The company said its electrophysiology division would keep expa...

Boston Scientific Faces Investor Lawsuit Alleging Misleading Statements About Electrophysiology Growth

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on X4 Pharmaceuticals (XFOR – Research Report), Boston ...

Analysts’ Top Healthcare Picks: X4 Pharmaceuticals (XFOR), Boston Scientific (BSX)

Healthcare is diverse sector of the economy. 


IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Portfolio Diversification to Investors

Boston Scientific ($BSX) announced an update on their ongoing clinical study. Boston Scientific (BSX) is backing a pilot trial called “Combined CM ...

Current Yield	N/A	Payout Ratio	0.00%
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BSX	$61.28	-2.05%	12.70M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BSX	$61.28	-2.0%	12.70M
3
4
5
6

BSX

BSX

Dividend Overview

Get Boston Scientific Corporation Data in Excel

Get Boston Scientific Corporation Data in Excel